BA-1049 is an orally active small molecule classified as a selective Rho-associated protein kinase 2 (ROCK2) inhibitor currently under clinical investigation for treating central nervous system cavernous… Read more
BA-1049 is an orally active small molecule classified as a selective Rho-associated protein kinase 2 (ROCK2) inhibitor currently under clinical investigation for treating central nervous system cavernous hemangiomas. By preserving blood-brain barrier integrity and reducing cerebral edema, this compound represents a significant development in neurovascular therapy. The collection of BA-1049 related compounds serves as a critical resource for analytical testing, providing the necessary reference standards for rigorous method validation and quality control. Researchers rely on these materials, including specific metabolites like 1-hydroxy-BA-1049 and stable isotope labelled versions, to support comprehensive impurity profiling. These high-quality reference materials enable the accurate identification and quantification of degradation products and metabolic pathways, ensuring reliability throughout preclinical and clinical studies while maintaining compliance with strict regulatory standards for pharmaceutical development.